Comments Requested on the Proposed Policies for the 340B Drug Pricing Program’s Alternative Dispute Resolution Process

Recently, HRSA issued a proposed rule that would revise the current 340B administrative dispute resolution (ADR) final rule (Dec. 14, 2020) with a new process. The ADR process is an administrative process designed to assist covered entities and manufacturers in resolving disputes regarding overcharging, duplicate discounts, or diversion, as outlined in the statute. Eligible entities for the 340B Drug Pricing Program include a number of rural healthcare facility types. Comments due January 30